529 related articles for article (PubMed ID: 29790582)
1. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
[TBL] [Abstract][Full Text] [Related]
2. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
3. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Kim CW; Addy C; Kusunoki J; Anderson NN; Deja S; Fu X; Burgess SC; Li C; Ruddy M; Chakravarthy M; Previs S; Milstein S; Fitzgerald K; Kelley DE; Horton JD
Cell Metab; 2017 Aug; 26(2):394-406.e6. PubMed ID: 28768177
[TBL] [Abstract][Full Text] [Related]
4. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ
Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823
[TBL] [Abstract][Full Text] [Related]
5. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.
Savage DB; Choi CS; Samuel VT; Liu ZX; Zhang D; Wang A; Zhang XM; Cline GW; Yu XX; Geisler JG; Bhanot S; Monia BP; Shulman GI
J Clin Invest; 2006 Mar; 116(3):817-24. PubMed ID: 16485039
[TBL] [Abstract][Full Text] [Related]
6. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
[TBL] [Abstract][Full Text] [Related]
7. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
[TBL] [Abstract][Full Text] [Related]
8. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
9. Acetyl-CoA carboxylase 2-/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions.
Abu-Elheiga L; Wu H; Gu Z; Bressler R; Wakil SJ
J Biol Chem; 2012 Apr; 287(15):12578-88. PubMed ID: 22362781
[TBL] [Abstract][Full Text] [Related]
10. The chloroform extract of Cyclocarya paliurus attenuates high-fat diet induced non-alcoholic hepatic steatosis in Sprague Dawley rats.
Lin Z; Wu ZF; Jiang CH; Zhang QW; Ouyang S; Che CT; Zhang J; Yin ZQ
Phytomedicine; 2016 Nov; 23(12):1475-1483. PubMed ID: 27765368
[TBL] [Abstract][Full Text] [Related]
11. Effect of Creosote Bush-Derived NDGA on Expression of Genes Involved in Lipid Metabolism in Liver of High-Fructose Fed Rats: Relevance to NDGA Amelioration of Hypertriglyceridemia and Hepatic Steatosis.
Zhang H; Li Y; Hu J; Shen WJ; Singh M; Hou X; Bittner A; Bittner S; Cortez Y; Tabassum J; Kraemer FB; Azhar S
PLoS One; 2015; 10(9):e0138203. PubMed ID: 26394137
[TBL] [Abstract][Full Text] [Related]
12. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
13. Hypertriglyceridemia in lecithin-cholesterol acyltransferase-deficient mice is associated with hepatic overproduction of triglycerides, increased lipogenesis, and improved glucose tolerance.
Ng DS; Xie C; Maguire GF; Zhu X; Ugwu F; Lam E; Connelly PW
J Biol Chem; 2004 Feb; 279(9):7636-42. PubMed ID: 14668345
[TBL] [Abstract][Full Text] [Related]
14. Naringin improves lipid metabolism in a tissue-engineered liver model of NAFLD and the underlying mechanisms.
Zhang X; Zhang Y; Gao W; Guo Z; Wang K; Liu S; Duan Z; Chen Y
Life Sci; 2021 Jul; 277():119487. PubMed ID: 33862107
[TBL] [Abstract][Full Text] [Related]
15. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
[TBL] [Abstract][Full Text] [Related]
16. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
[TBL] [Abstract][Full Text] [Related]
17. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
18. Green tea polyphenols ameliorate non-alcoholic fatty liver disease through upregulating AMPK activation in high fat fed Zucker fatty rats.
Tan Y; Kim J; Cheng J; Ong M; Lao WG; Jin XL; Lin YG; Xiao L; Zhu XQ; Qu XQ
World J Gastroenterol; 2017 Jun; 23(21):3805-3814. PubMed ID: 28638220
[TBL] [Abstract][Full Text] [Related]
19. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway.
Chen S; Sun S; Feng Y; Li X; Yin G; Liang P; Yu W; Meng D; Zhang X; Liu H; Zhang F
Eur J Pharmacol; 2023 Aug; 952():175808. PubMed ID: 37263401
[TBL] [Abstract][Full Text] [Related]
20. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
